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Clinical and genetic features of cervical
dystonia in a large multicenter cohort
ABSTRACT
Objective: To characterize the clinical and genetic features of cervical dystonia (CD).
Methods: Participants enrolled in the Dystonia Coalition biorepository (NCT01373424) with ini-
tial manifestation as CD were included in this study (n 5 1,000). Data intake included demo-
graphics, family history, and the Global Dystonia Rating Scale. Participants were screened for
sequence variants (SVs) in GNAL, THAP1, and Exon 5 of TOR1A.
Results: The majority of participants were Caucasian (95%) and female (75%). The mean age at
onset and disease duration were 45.5 6 13.6 and 14.6 6 11.8 years, respectively. At the time
of assessment, 68.5% had involvement limited to the neck, shoulder(s), and proximal arm(s),
whereas 47.4% had dystonia limited to the neck. The remaining 31.5% of the individuals exhibited
more extensive anatomical spread. A head tremor was noted in 62% of the patients. Head tremor
and laryngeal dystonia were more common in females. Psychiatric comorbidities, mainly depression
and anxiety, were reported by 32% of the participants and were more common in females. Family
histories of dystonia, parkinsonian disorder, and tremor were present in 14%, 11%, and 29%of the
patients, respectively. Pathogenic or likely pathogenic SVs in THAP1, TOR1A, and GNAL were
identified in 8 participants (0.8%). Two individuals harbored novel missense SVs in Exon 5 of
TOR1A. Synonymous and noncoding SVs in THAP1 and GNAL were identified in 4% of the cohort.
Conclusions: Head tremor, laryngeal dystonia, and psychiatric comorbidities are more common in
female participants with CD. Coding and noncoding variants in GNAL, THAP1, and TOR1A make
small contributions to the pathogenesis of CD. Neurol Genet 2016;2:e69; doi: 10.1212/
NXG.0000000000000069
GLOSSARY
1KG 5 1000 Genomes Project; CADD 5 Combined Annotation-Dependent Depletion; CD 5 cervical dystonia; DC 5 Dys-
tonia Coalition; ESE 5 exonic splicing enhancer; ESS 5 exonic splicing silencer; EVS 5 Exome Variant Server; ExAC 5
Exome Aggregation Consortium; GDRS 5 Global Dystonia Rating Scale; HRM 5 high-resolution melting; miRNA 5 micro-
RNA; PolyPhen-2 5 Polymorphism Phenotyping version 2; SV 5 sequence variant; SWEDDs 5 scans without evidence of
dopaminergic deficit; UTHSC 5 University of Tennessee Health Science Center.
Cervical dystonia (CD) is the most common adult-onset isolated dystonia.1,2 The percentage of
patients with CD with head tremor, neuropsychiatric comorbidities, and spread of dystonia to
other anatomical segments is mostly unknown in large multicenter clinical series. Genetic factors
are believed to be important given that most large clinical series report a positive family history in
approximately 10% of probands.3–5 Although sequence variants (SVs) in THAP1, GNAL, and
From the Departments of Neurology and Anatomy & Neurobiology (M.S.L., S.R.V., J.X., M.M.T.), University of Tennessee Health Science
Center, Memphis, TN; Department of Neurology (J.S.P., L.J.W.), Washington University School of Medicine, St. Louis, MO; Departments of
Neurology (A.R.R.), Human Genetics, and Pediatrics (H.A.J.), School of Medicine, Emory University, Atlanta, GA; Department of Neurology
(P.H.), Vanderbilt University, Nashville, TN; Department of Neurological Sciences (C.L.C.), Rush University, Chicago, IL; Institute of Neuro-
genetics (A.W., J. Junker), University of Lübeck, Germany; Department of Neurology (J. Jankovic), Baylor College of Medicine, Houston, TX;
Department of Neurology (R.L.B.), University of Rochester, NY; Department of Neurology (S.G.R.), University of Maryland, Baltimore, MD;
Department of Neurology (R.L.R.), University of Florida, Gainesville, FL; Department of Neurology (B.D.B.), University of Colorado Denver
School of Medicine, Aurora, CO; Center of Excellence in Neuroscience (S.C.), University of Montreal, QC, Canada; Mirken Department of
Neurology (L.S.), Mt. Sinai Beth Israel Medical Center, New York, NY; Booth Gardner Parkinson’s Care Center (P.A.), Kirkland, WA; and
Department of Neurology (N.P.S.), University of Alabama at Birmingham, AL.
Coinvestigators are listed at Neurology.org/ng.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/ng for full disclosure forms. The Article Processing
Charge was paid by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially.
Neurology.org/ng © 2016 American Academy of Neurology 1
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Exon 5 of TOR1A have been identified in
small percentages of participants with isolated
CD, the relative contributions of dystonia-
associated genes to mainly adult-onset (.20
years)6 CD have not been fully character-
ized.3,5,7–14 In this study, we detail the clinical
and genetic features of CD in a large multi-
center cohort.
METHODS Study design and patients. The Dystonia
Coalition (DC, www.rarediseasesnetwork.org/dystonia/) has
developed a biospecimen repository (Coriell; Camden, NJ) and
an associated clinical database to be used as a resource for
dystonia research (http://clinicaltrials.gov/show/NCT01373424).
Participants included in the analyses described herein were the
first 1,000 with reported onset of dystonia in the nonlaryngeal,
nonpharyngeal neck muscles. These participants were enrolled
between January 5, 2011, and September 21, 2014. Data
collection for the DC included the following: blood for the
extraction of DNA and lymphocytes, Global Dystonia Rating
Scale (GDRS), video examination, and clinical data elements
(demographics, age at onset, site of onset, sensory tricks,
anatomical distribution of dystonia, history of psychiatric
disorders, and family history [dystonia, parkinsonism, and
tremor]). Raters were also asked to indicate whether the neck was
affected by tremor. The Dystonia Genetic Consortium is an
international collaboration of neurologists interested in the
genetics of dystonia and closely related neurogenetic disorders.
Biological specimens acquired by the Dystonia Genetic
Consortium are stored in the Department of Neurology at the
University of Tennessee Health Science Center (UTHSC).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the ethics committees of
all participating centers. All participants gave written informed
consent for participation in the study and inclusion in the biospe-
cimen and video repositories.
Genetic screening. Because of the limited amounts of DNA
available for this project (2 mg per participant) and questions
related to the pathogenicity of CIZ1 and ANO3 SVs in partic-
ipants with isolated dystonia, a combination of high-resolution
melting (HRM) and Sanger sequencing was restricted to coding
and contiguous noncoding regions of THAP1, GNAL, and
Exon 5 of TOR1A.3,5,8,10,15 Exon 5 of TOR1A harbors the
classic DYT1 DGAG mutation, and cosegregating pathogenic
SVs have not been identified in other exons of TOR1A.7,8,15,16
After the identification of 2 novel SVs in Exon 5 of TOR1A, an
additional 1,160 DNA samples from the UTHSC Dystonia
Genetics Consortium biorepository were also screened for
these and other SVs within Exon 5 of TOR1A (table e-1 at
Neurology.org/ng). Cases with known mutations in TOR1A
and other dystonia-associated genes were excluded from this
secondary screening effort.
In silico mutation prediction programs SIFT, MutationTast-
er, Polymorphism Phenotyping version 2 (PolyPhen-2), and
Combined Annotation-Dependent Depletion (CADD) were used
to evaluate the pathogenicity of novel and previously reported
missense SVs.17–20 TargetScanHuman 6.2 (www.targetscan.org)
was used to search for predicted microRNA (miRNA) targets
within loci harboring SVs.21 Human Splicing Finder 3.0
(www.umd.be/HSF) was used to predict the effects of identi-
fied SVs on splicing motifs including acceptor and donor splice
sites, and branch point and auxiliary sequences known to either
enhance (exonic splicing enhancers [ESEs]) or repress (exonic
splicing silencers [ESSs]) splicing.22 The allele frequency of the
identified SVs was compared with the frequencies reported in
Exome Variant Server (EVS, evs.gs.washington.edu/EVS/),
1000 Genomes Project (1KG, www.1000genomes.org), and
Exome Aggregation Consortium (ExAC, exac.broadinstitute.
org). American College of Medical Genetics and Genomics
guidelines were used for the classification of SVs as “patho-
genic,” “likely pathogenic,” “uncertain significance,” “likely
benign,” or “benign.”23 Details of HRM, Sanger sequencing,
and variant analysis are included in appendix e-1 and table e-2.
Statistical analysis. Fisher exact tests (2-tailed) were used to
compare female-male frequencies. The x2 statistic (2-tailed) was
used to compare case-control genotype frequencies. Two-tailed t
tests were used to determine whether age, age at onset, duration,
and scores on rating scales differed between women and men. The
Pearson correlation coefficient (r) was used to measure the
strength of linear associations between GDRS scores and
number of affected anatomical segments, dystonia duration,
and dystonia age at onset. An alpha (a) of 0.05 was chosen for
statistical significance.
RESULTS The majority (95%) of participants were
Caucasian females (table 1). The mean age at onset
and disease duration for the entire cohort of 1,000
participants were 45.5 and 14.6 years, respectively. A
high percentage of the 1,000 participants with CD
had a head tremor (62%), and head tremor was more
common in females than in males. Total GDRS
scores did not differ between males and females.
The majority of participants (68.5%) had anatomical
involvement limited to the neck 6 shoulder(s) and
proximal arm(s). Less than half of the patients
enrolled in this cohort were judged to have isolated
neck involvement (47.4%). Females with CD were
more likely to manifest laryngeal dystonia. Otherwise,
there were no significant effects of sex on patterns of
anatomical involvement. Age at onset decreased with
the number of affected anatomical segments and
GDRS total score (table 2). Dystonia duration
increased with the number of affected anatomical seg-
ments and GDRS total score.
Themajority of participants reported at least 1 sen-
sory trick (71%), which did not differ between males
and females. Psychiatric disorders were reported more
commonly by females (35%) than males (23%) and
included, in the order of frequency, isolated depres-
sion, combined anxiety and depression, and isolated
anxiety. Although myoclonus (2%) and parkinsonism
(1%) were reported in small numbers of participants,
etiologic diagnosis was not part of the study protocol.
A family history of dystonia was reported by 14%
of the participants (table 1). Among the participants
with a family history, 2 participants reported that
both their mother and father were affected, whereas
46 reported an affected mother and 27 reported an
affected father. A family history of parkinsonism was
2 Neurology: Genetics
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Table 1 Clinical features of the study population
Total Female Male Sex effect, p value
Participants 1,000 750 250
Race
White or Caucasian 945 (94.5)a 714 (95.2) 231 (92.4) 0.11
American Indian or Alaska Native 6 (0.6) 4 (0.53) 2 (0.8) 0.64
Asian American 7 (0.7) 3 (0.40) 4 (1.6) 0.70
Black or African American 22 (2.2) 17 (2.3) 5 (2.0) 1.00
Not reported 20 (2.0) 12 (1.6) 8 (3.2) 0.12
Age, y 60.2 6 11.7, median
61 (53–68)b
61.1 6 11.1, median
62 (54–69)
57.5 6 12.7, median
59 (49–66)
2.3E-05
Age at onset, y 45.5 6 13.6, median
46 (37–55)
45.8 6 13.6, median
46 (37–55)
44.8 6 13.1, median
46 (35–54)
0.34
Duration, y 14.6 6 11.8, median
11 (5–21)
15.3 6 12.01, median
12 (6–22)
12.7 6 11.1, median
10 (5–18)
0.0022
Head tremor 615 (61.5) 482 (64.3) 133 (53.2) 0.0021
Global Dystonia Rating Scale—total score 7.93 6 5.38, median
7 (5–10)
7.90 6 5.44, median
11 (5–10)
8.02 6 5.20, median
11 (5–10)
0.77
Global Dystonia Rating Scale—neck score 5.15 6 2.07, median
5 (4–7)
5.06 6 2.01, median
5 (4–7)
5.43 6 2.23, median
5 (4–7)
0.013
Sensory trick(s) 708 (70.8) 530 (70.7) 178 (71.2) 0.94
Psychiatric disorder(s) 319 (31.9) 262 (34.9) 57 (22.8) 3.1E-04
Depression 121 (12.1) 97 (12.9) 24 (9.6) 0.18
Anxiety disorder 81 (8.1) 68 (9.1) 13 (5.2) 0.060
Depression and anxiety disorder 102 (10.2) 82 (10.9) 20 (8.0) 0.23
Depression and anxiety disorder and
other psychiatric disorders
3 (0.3) 3 (0.4) 0 (0) 0.58
Other psychiatric disorder(s) 12 (1.2) 12 (1.6) 0 (0) 0.045
Current anatomical distribution of dystonia
Neck 474 (47.4) 359 (47.9) 115 (46.0) 0.66
Eyes and upper face 102 (10.2) 80 (10.7) 22 (8.8) 0.47
Lower face 88 (8.8) 72 (9.6) 16 (6.4) 0.16
Jaw and tongue 52 (5.2) 42 (5.6) 10 (4.0) 0.41
Larynx 81 (8.1) 72 (9.6) 9 (3.6) 0.0019
Shoulder and proximal arm 395 (39.5) 296 (39.5) 99 (39.6) 1.00
Distal arm and hand 167 (16.7) 131 (17.5) 36 (14.4) 0.28
Pelvis and proximal leg 7 (0.7) 4 (0.5) 3 (1.2) 0.38
Distal leg and foot 27 (2.7) 22 (2.9) 5 (2.0) 0.51
Trunk 49 (4.9) 35 (4.7) 14 (5.6) 0.61
Neck 6 shoulder(s) 685 (68.5) 507 (67.6) 178 (71.2) 0.31
Examination
Myoclonus 16 (1.6) 15 (2.0) 1 (0.4) 0.14
Parkinsonism 10 (1.0) 7 (0.93) 3 (1.2) 0.72
Family history
Dystonia negative 760 (76.0) 570 (76.0) 190 (76.0) 1.00
Dystonia unknown or unreported 101 (10.1) 80 (10.7) 21 (8.4) 0.33
Dystonia positive 139 (13.9) 100 (13.3) 39 (15.6) 0.40
Parkinsonism negative 815 (81.5) 601 (80.1) 214 (85.6) 0.060
Parkinsonism unknown or unreported 74 (7.4) 55 (7.3) 19 (7.6) 0.89
Continued
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reported by 11%. Parkinsonism was reported more
commonly by females (13%) than males (7%). Over-
all, 29% of participants reported a family history of
tremor and there was no significant difference
between females (30%) and males (24%). The pres-
ence or absence of dystonia, parkinsonism, and
tremor in family members was not confirmed by
face-to-face examinations or telephone interviews.
Twelve coding SVs (tables 3 and 4, figure) pre-
dicted to be possibly pathogenic or deleterious by at
least 1 of 4 (SIFT, MutationTaster, PolyPhen-2, and
CADD) in silico prediction programs were identified
in our cohort. In addition, the classic DGAG deletion
mutation in TOR1A was identified in 1 participant
(tables 3 and 4).
A definite family history of CD was reported by a
single proband with a GNAL SV (DYS87,
p.V354M). The mother of DYS87 (figure, II-A)
had CD with age at onset of 43 years. Family history
was inconclusive in another GNAL pedigree
(DYS497). The mother of DYS497 (figure, I-A)
had a low-frequency right-hand tremor with onset
in her late 60s, approximately 5 years after an appar-
ent episode of tardive dyskinesias due to neuroleptic
medication treatment of a psychiatric disorder.
Reportedly, the tremor did not improve with medical
treatment. Gait was shuffling and hand writing was
tremulous but not micrographic. Participant I-A from
pedigree DYS497 was never formally diagnosed with
drug-induced parkinsonism, Parkinson disease, or
SWEDDs (scans without evidence of dopaminergic
deficit).
Family histories of tremor were reported by 2 pro-
bands with TOR1A missense SVs (figure). The father
of DYS266 had a late adult-onset tremor of histori-
cally unreliable anatomical distribution. The brother
of DYS1565 was treated with deep brain stimulation
for severe head and arm tremors. Two sisters (II-B
and II-E) also had head tremors. Of note, participants
I-A, II-B, and II-D had onset of tremor in their 40s
and all 3 died of cancer, whereas participant II-E died
after an automobile accident.
Among coding SVs, the THAP1 p.S51R SV had
the highest CADD Phred score (27.1) and showed
relatively high penetrance with multiple affected in-
dividuals in the pedigree (figure). The proband’s sister
(figure, III-D), also enrolled in the DC biorepository,
harbors the same p.S51R SV but had initial onset in
the distal arm-hand anatomical segment at 32 years of
age that has now progressed to generalized dystonia.
One of her 2 daughters (IV-F) has generalized dysto-
nia with onset in the distal arm-hand at 7 years of age,
and a granddaughter (V-I) has CD and possible lower
extremity dystonia with onset at 15 years of age. Par-
ticipant IV-E had onset of dystonia in the neck and
shoulder in her mid-20s with spread to the right distal
arm and hand by her early 30s. Participant IV-E is
now 43 years old and has generalized dystonia with
additional involvement of her left arm and leg. Her
daughter, participant V-H, had onset of right-arm
dystonia at 13 years of age. Participant III-B has spas-
modic dysphonia and participant V-G has dystonia of
unknown anatomical distribution.
Synonymous SVs were identified in GNAL
(p.R22R, p.A338A) and THAP1 (p.P19P). The
GNAL R22R SV was found in ExAC, 1KG, and
EVS, and in 6 participants within the DC. GNAL
R22R was not enriched in the DC cohort. However,
the R22R variant had a CADD Phred score of 22.1
and is predicted to break an ESE site. GNAL A338A
was identified in 33 patients in the DC cohort, all
heterozygotes. In comparison with ExAC, GNAL
A338A was enriched in the DC cohort (x2 5
13.034, p 5 0.0003). Moreover, this variant is
Table 1 Continued
Total Female Male Sex effect, p value
Parkinsonism positive 111 (11.1) 94 (12.5) 17 (6.8) 0.014
Tremor negative 650 (65.0) 472 (62.9) 178 (71.2) 0.018
Tremor unknown or unreported 63 (6.3) 51 (6.8) 12 (4.8) 0.30
Tremor positive 287 (28.7) 227 (30.3) 60 (24) 0.063
aUnless otherwise specified data are mean 6 SDs or n (%).
b25%–75% quartiles.
Table 2 Effect of age at onset and disease duration on distribution and severity of dystonia
No. of anatomical segments GDRS total score GDRS neck score
Age at onset 20.090 (20.15 to 20.028), p 5 0.0066a 20.066 (20.127 to 20.0039), p 5 0.037 20.042 (20.10 to 0.020), p 5 0.18
Duration 0.115 (0.053 to 0.18), p 5 7.6E-05 0.071 (0.010 to 0.130), p 5 0.024 0.031 (20.031 to 0.093), p 5 0.33
Abbreviation: GDRS 5 Global Dystonia Rating Scale.
a Pearson correlation coefficients with confidence intervals.
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Table 3 Bioinformatic analysis of SVs identified in participants with CD
Gene
Participant
(s) cDNA Protein
ACMG
classification dbSNP
Minor allele frequency In silico pathogenicity/deleteriousness Splicing (human splice finder 3.0)
EVS 1KG ExAC DC SIFT MutationTaster PolyPhen-2
CADD
raw
CADD
Phred
Splice
site
distance
HSF
matrices
ESE
finder
ESR
sequences
GNAL DYS1579 c.40C.T p.Q14* Pathogenic 0.0005 NA Disease
causing
NA 2.72 22.5 142 None None ESE site
broken
GNAL n 5 5 c.66C.T p.R22R Uncertain
significance
rs73397885 0.01 0.008 0.00562 0.0025 Tolerated Polymorphism NA 2.43 22.1 79 New donor
site
ESE site
broken
None
GNAL DYS497 c.139C.A p.L47I Likely
pathogenic
0.0005 Damaging Disease
causing
Benign 2.55 22.3 6 None ESE site
broken
ESE site
broken
GNAL DYS734 c.214C.G p.P72A Likely
pathogenic
0.0005 Tolerated Disease
causing
Benign 1.49 15.9 4 None None New ESS
site
GNAL n 5 135 c.218119C.A NA Likely benign rs1895689 0.000307 0.348 0.2968 0.078 NA NA NA 1.16 14.1 19 None None None
GNAL n 5 74 c.932-7T.G NA Benign rs3892113 0.06 0.044 0.0628 0.041 NA NA NA 0.05 4.1 7 None None None
GNAL n 5 33 c.1014C.T p.A338A Uncertain
significance
rs41289504 0.01 0.0034 0.008831 0.016 Tolerated Disease
causing
NA 2.01 19.2 15 None ESE site
broken
New ESS
site
GNAL DYS41 c.1018G.A p.G340S Likely
pathogenic
rs142792291 0.0001538 0.0000249 0.0005 Tolerated Disease
causing
Probably
damaging
2.13 20.3 19 New
acceptor
site
None New ESS
site
GNAL DYS87 c.1060G.A p.V354M Pathogenic 0.0005 Damaging Disease
causing
Probably
damaging
2.57 22.4 61 None ESE site
broken
New ESS
site
THAP1 DYS1729 c.57C.T p.P19P Uncertain
significance
rs146087734 0.00023 0.000099 0.0005 Tolerated Disease
causing
NA 1.93 18.6 14 None None None
THAP1 DYS1706 c.7119C.A NA Likely
pathogenic
rs200209986 0.001999 0.001291 0.0005 NA NA NA 0.93 12.6 9 None None None
THAP1 DYS88 c.153C.G p.S51R Pathogenic 0.0005 Damaging Disease
causing
Probably
damaging
5.06 27.1 81 None None None
THAP1 DYS1068 c.427A.G p.M143V Uncertain
significance
rs374512193 0.00007 0.00007413 0.0005 Tolerated Polymorphism Benign 0.85 12.1 159 New
acceptor
site
None None
TOR1A
Exon 5
DYS266 c.823A.G p.K275E Uncertain
significance
rs148036363 0.0002307 0.0003789 0.0005 Tolerated Disease
causing
Probably
damaging
2.27 21.4 74 None ESE site
broken
None
TOR1A
Exon 5
DYS1754 c.907_909
delGAG
p.E303del Pathogenic rs724159981 0.0005 NA Disease
causing
NA 2.73 22.5 158 None ESE site
broken
New ESS
site
TOR1A
Exon 5
DYS1565 c.962C.T p.T321M Uncertain
significance
0.00001647 0.0005 Damaging Disease
causing
Probably
damaging
2.06 19.6 213 None None New ESS
site
cDNA/protein (GNAL-NM_001142339.2/NP_001135811.1, THAP1- NM_018105.2/NP_060575.1, TOR1A-NM_000113.2/NP_000104.1).
Abbreviations: 1KG 5 1000 Genomes Project; ACMG 5 American College of Medical Genetics and Genomics; CADD 5 Combined Annotation-Dependent Depletion; CD5 cervical dystonia; cDNA 5 complementary
DNA; dbSNP 5 Single Nucleotide Polymorphism database; DC 5 Dystonia Coalition; ESE 5 exonic splicing enhancer; ESR 5 exonic splicing regulator; ESS 5 exonic splicing silencer; EVS 5 Exome Variant Server;
ExAC 5 Exome Aggregation Consortium; NA 5 not applicable; PolyPhen-2 5 Polymorphism Phenotyping version 2; SV 5 sequence variant.
Splice site distance 5 base pairs from nearest splice site in either the 59 or 39 direction.
N
eurology:G
enetics
5
ª
2016
A
m
erican
A
cad
em
y
o
fN
euro
lo
g
y.U
nautho
rized
rep
ro
d
uctio
n
o
fthis
article
is
p
ro
hib
ited
.
predicted to be disease causing by MutationTaster
and has a CADD Phred score of 19.2 and may gen-
erate a new ESS site. THAP1 P19P is categorized as
disease causing by MutationTaster and was found in
1 participant in the DC cohort.
Noncoding SVs were identified in GNAL and
THAP1. A c.218119C.A SV in GNAL is predicted
to be marginally deleterious by CADD but is found at
high frequency within the ExAC database. The
c.932-7T.G SV in GNAL is frequent in the DC,
ExAC, and 1KG databases and benign (table 3).
None of the coding or noncoding variants detected
in this study are predicted to disrupt miRNA-binding
domains.
Follow-up screening of TOR1A Exon 5 identified
3 patients with the classic DYT1 DGAG deletion
(table e-1).7,8 In addition, 1 participant
(DYS_85085, figure) was found to have the same
c.962C.T (p.T321M) SV as DC DYS1565.
DYS_85085 was initially evaluated at 53 years of
age for mild gait dysfunction and found to have mild
spasticity with bilateral Babinski responses and
hyperreflexia of undetermined etiology. Despite
mild foot drop, she was able to walk unaided at 66
years of age. At 59 years of age, she developed abnor-
mal head posturing with subsequent spread of dys-
tonia to her arms, worse in the left arm than in the
right. On the most recent examination, she had CD
with an irregular/jerky head tremor, along with
bilateral arm tremors. Her deceased brother and
father had a similar gait abnormality. DNA acquired
from an alive and neurologically normal brother did
not harbor the c.962C.T SV. The proband’s
deceased mother and maternal grandmother had
jerky head tremors but normal gait.
DISCUSSION We characterized the clinical features
of CD and contributions of known isolated
dystonia-associated genes to the etiopathogenesis
of CD and established a platform for future
clinical and genetic studies of dystonia. The
demographics of our cohort are compatible with
the previous epidemiologic studies of CD and
other forms of dystonia.24 In particular, CD is
more common in females than in males and,
apparently, less common in African Americans
than in Caucasians.1,25 Women with CD were
more likely than men to exhibit a head tremor,
develop laryngeal dystonia, and report a history of
at least the onset of a psychiatric disorder. However,
the effect of sex on the frequencies of psychiatric
conditions should be interpreted with caution given
that we did not use a control cohort for the
nongenetic aspects of our study.
As suggested by our data set, the boundaries
between focal and segmental dystonia and definition
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of CD are often imprecise.26 In the neck, for example,
the trapezius and levator scapulae muscles insert on
the scapula and cross the neck and shoulder anatom-
ical regions. In our study, only 47% of participants
were deemed to exhibit isolated neck involvement,
whereas 69% were reported to manifest dystonia in
the neck and shoulder(s). The current classification of
dystonia states that CD is “considered a form of focal
dystonia, although by convention the shoulder can be
included as well as the neck.”6
Small percentages of participants were reported to
have had myoclonus (2%) or parkinsonism (1%).
Because of the limiting quantities of DNA available
for this study, participants with myoclonus were not
screened for mutations in SGCE, KCTD17, RELN,
or CACNA1B. In addition, neurophysiologic studies
were not performed to differentiate myoclonic from
dystonic jerks and we did not formally diagnose the
cause of parkinsonism in this small group of 10 pa-
tients or differentiate dystonic from nondystonic
causes of SWEDDs.27
In our cohort, a considerable majority of partici-
pants had a head tremor. The presence of tremor in
dystonia and dystonia in patients with various forms
of tremor including essential tremor or “isolated
tremor” has received increasing attention in the recent
medical literature.28,29 The presence of either dystonia
or isolated tremor in individuals within some pedi-
grees suggests that subtypes of isolated tremor may
exist and share genetic etiologies with some forms of
Figure Pedigrees of probands with missense sequence variants in GNAL, THAP1, and TOR1A
Arrows 5 probands; filled symbols 5 affected; half-filled symbols 5 possibly affected.
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dystonia.30 Of note, the high family history of tremor
(29%) in our cohort exceeded the combined family
histories of parkinsonism and dystonia.
A role for genetic factors in the etiopathogenesis
of CD has long been recognized.31,32 In a review of
266 patients with isolated CD from a single center,
12% had a positive family history of dystonia.32
Similar percentages of participants with first- or
second-degree relatives with dystonia have been
reported in large genetic screening studies of CD
and other isolated dystonia cohorts.3,4,10 There-
fore, the 14% of CD participants with a positive
family history of dystonia is in line with the pre-
vious works.
A small but noteworthy percentage (11%) of
participants in our CD cohort reported a positive
family history of parkinsonism. In this regard, post-
mortem pathologic studies and animal models of
dystonia suggest that mild damage to the dopamin-
ergic nigrostriatal pathway may contribute to the
pathogenesis of dystonia.33,34 However, isolated
dystonia has not been shown to be a risk factor
for Parkinson disease and vice versa, and family
members were not accessible for neurologic exami-
nations to diagnose SWEDDs, Parkinson disease,
or other parkinsonian disorders.
Generally, the genetic contributions to CD iden-
tified in this study were small; patients with patho-
genic or likely pathogenic missense SVs tended to
show evidence of spread to contiguous anatomical
segments over time, and among those genes interro-
gated, GNAL had the largest impact (tables 3 and 4).
We identified several pathogenic or likely patho-
genic GNAL missense variants in our cohort.23
Likely due to the focus on CD, the frequency of
missense variants in GNAL reported herein was
modestly higher than that reported in other screen-
ing studies.5,35 Perhaps most importantly, a synon-
ymous variant of uncertain significance (p.A338A)
was enriched in our CD cohort in comparison with
the population controls contained in the ExAC data-
base. Accordingly, A338A may increase the risk of
developing CD.
Not unexpectedly, SVs in THAP1 were infre-
quent in our CD cohort. In previous screening
studies, pathogenic or likely pathogenic THAP1
missense SVs were found in less than 1% of the
patients with mainly adult-onset isolated dysto-
nia.10,11 The synonymous THAP1 variant
(p.P19P) identified in 1 participant in our cohort
was previously reported in a patient with segmental
craniocervical dystonia.10 The c.7119C.A in-
tronic variant was found in 1 participant in this
study and previously reported as enriched in pa-
tients with dystonia in comparison with neurolog-
ically normal controls.36
Notably, our screening efforts exposed a non-
DGAG SV in TOR1A (c.962C.T, p.T321M) in 2
pedigrees from different regions of the United States.
Family history information acquired from the pro-
bands suggested that these pedigrees were unrelated.
We also identified another SV in TOR1A
(c.823A.G, p.K275E) of uncertain significance.
Other TOR1A variants of uncertain significance have
been described in single individuals with dystonia.37,38
Both p.K275E and p.T321M are contained at very
low frequencies within the ExAC database, and all 3
probands harboring these TOR1A SVs reported a
positive family history of dystonia. Studies of
p.K275E and p.T321M torsinA in cellular systems
and animal models should provide important and
novel insights into the biology of dystonia. The classic
TOR1A DGAG mutation is infrequent (2/1,319 pa-
tients 5 0.15%) in participants with dystonia onset
in the neck.
Given that our screenings were limited to
THAP1, GNAL, and Exon 5 of TOR1A, the poten-
tial roles of CIZ1, ANO3, and Exons 1, 2, 3, and 4
of TOR1A in the pathogenesis of CD remain
uncertain. In addition, we did not interrogate pro-
moter and deep intronic regions for variants of pos-
sible pathogenic significance and cannot exclude
the possibility that some participants in our cohort
harbored large deletion mutations in these or other
dystonia-associated genes. Conversely, those
missense and noncoding variants reported herein
were not subjected to cosegregation analyses or
downstream molecular and cellular assays of
deleteriousness.
Our data set provides a comprehensive presenta-
tion of CD phenotypes and rational overview of CD
genetics. The majority of patients with CD have a
head tremor and an important percentage exhibit
spread to contiguous anatomical regions, have per-
sonal histories of psychiatric disorders, and have
family histories of tremor and dystonia. Although
coding and noncoding SVs in GNAL, THAP1, and
TOR1A contribute to the development of CD, the
yield of clinical genetic testing for pathogenic SVs in
this collection of genes will be low in sporadic cases
of CD, particularly in those participants without any
evidence of spread to other anatomical segments,
but may be considered in individuals from multiplex
pedigrees with dystonia. The prevalence of
pathogenic and likely pathogenic SVs in dystonia-
associated genes reported herein should be consid-
ered a minimum because we did not exclude copy
number variants or include GCH1, SGCE,
KCTD17, RELN, CACNA1B, HPCA, and TAF1
in our screenings. Clinical genetic testing of TOR1A
in patients with dystonia should not be limited to
discovery of the classic DGAG mutation given that
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other TOR1A SVs may be pathogenic. Future stud-
ies into the molecular and cellular biology of CD
should benefit from the identification of other
genetic etiologies and must consider potential bio-
logical commonalities with Parkinson disease, iso-
lated tremor, and psychiatric disorders, principally
depression and anxiety.
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